Compare GSK plc (GSK) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Teradyne, Inc. — how do they compare? GSK plc trades at $52.72 (market cap $101.34B), while Teradyne, Inc. trades at $323.51 (market cap $53.56B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TER | |
|---|---|---|
Market Cap | $101.34B | $53.56B |
Sector | Health | Technology |
52-Week High | $61.18 | $483.84 |
52-Week Low | $36.20 | $90.15 |
Enterprise Value | $121.95B | $53.39B |
Dividend Yield | 3.49% | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Teradyne (TER) trades at $322.19, down 8.79% over 24 hours, reflecting recent market pressure despite strong earnings beats. The stock shows bearish technical signals with support near $308, while fundamentals reveal robust profitability with 22.55% net margins and 28.75% ROE. Recent news highlights AI-driven growth in semiconductor testing, with Q2 2026 earnings anticipated on July 28, 2026.
Outlook remains positive given analyst consensus of $453.60 price target and 64.52% buy ratings, though high valuations (P/E 63.47) and technical weakness pose near-term risks. Long-term growth is supported by expanding AI infrastructure demand, but investors should monitor competitive pressures and execution on Q2 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
